Given the biological and clinical heterogeneity of neuroblastoma, risk stratification is vital to
determining appropriate treatment. Historically, most patients with high‐risk neuroblastoma …

To improve our understanding of ovarian cancer, we performed genome-wide analyses of
45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without …

Purpose: We investigated MYCN-regulated molecular pathways in castration-resistant
prostate cancer (CRPC) classified by morphologic criteria as adenocarcinoma or …

Simple Summary Metastatic prostate cancer is traditionally treated with androgen
deprivation therapy. The introduction of second-generation antiandrogens into clinical …

The MYC oncogenes and p53 have opposing yet interrelated roles in normal development
and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of …

Neuroblastoma is a pediatric cancer arising from sympathetic nervous system. Remarkable
heterogeneity in outcomes is one of its widely known features. One of the traits strongly …

Neuroblastoma (NBL) originating from the sympathetic nervous system is the most prevalent
solid tumor in infancy. Although there is sufficient variability in prognosis among different …

Genomic information from human patient samples of pediatric neuroblastoma cancers and
known outcomes have led to specific gene lists put forward as high risk for disease …

Abstract Cyclosporin A (CsA) induces DNA double-strand breaks in LIG4 syndrome
fibroblasts, specifically upon transit through S-phase. The basis underlying this has not been …

Neuroblastoma (NB) is a pediatric tumor of the sympathetic nervous system. Survival
remains poor for the almost 40% of patients with high-risk NB. Targeted therapy options for …